135 related articles for article (PubMed ID: 9815603)
1. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
3. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
[TBL] [Abstract][Full Text] [Related]
4. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
[TBL] [Abstract][Full Text] [Related]
5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
6. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
[TBL] [Abstract][Full Text] [Related]
7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
8. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
Rodriguez CO; Gandhi V
Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
[TBL] [Abstract][Full Text] [Related]
9. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
Verhoef V; Fridland A
Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
[TBL] [Abstract][Full Text] [Related]
10. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
12. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
Kisor DF
Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
[TBL] [Abstract][Full Text] [Related]
14. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Gandhi V; Plunkett W
Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
[TBL] [Abstract][Full Text] [Related]
15. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
18. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
[TBL] [Abstract][Full Text] [Related]
19. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
20. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
